Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
  • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
  • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P13/00—Preparation of nitrogen-containing organic compounds
  • C12P13/04—Alpha- or beta- amino acids
  • C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
  • C12P13/227—Tryptophan
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
  • C12P17/10—Nitrogen as only ring hetero atom
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P19/00—Preparation of compounds containing saccharide radicals
  • C12P19/26—Preparation of nitrogen-containing carbohydrates
  • C12P19/28—N-glycosides
  • C12P19/30—Nucleotides
  • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
  • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
  • C12P41/004—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction

Definitions

• the present invention relates to the use of monoclonal antibodies to catalyze stereochemical
• Monclonal antibodies are immunoglobulins produced by hybridoma cells.
• a monoclonal antibody reacts with a single antigenic determinant and provides greater specificity than a conventional, serum-derived antibody.
• screening a large number of monoclonal antibodies makes it possible to select an individual antibody with desired specificity, avidity, and isotype.
• Hybridoma cell lines provide a constant, inexpensive source of chemically identical antibodies and preparations of such antibodies can be easily
• Antigen recognition by a monoclonal antibody is attributable to a specific combining site in the N-terminal region of the immunoglobulin (Ig) molecule.
• Ig molecules are thought to react with antigens via the same types of short range forces characteristic of all
• Antigen-antibody Antigen-antibody
• Monoclonal antibodies have also been used to recover materials by immunoadsorption chromatography, e.g., Milstein, C., 1980, Scientific American 243:66, 70. However, it has not been suggested that
• monoclonal antibodies can be used to catalyze chemical reactions. Indeed, the field of catalysis has developed independently from the field of immunology. The only reported attempt at using antibodies as catalysts, of which applicants are aware resulted only in insignificant rate enhancement of the desired reaction. G.P. Royer, 1980, Advances in Catalysis 29:197-227.
• reaction can be expressed in terms of the equilibrium constant characterizing the equilibrium between the reactants, the intermediate, and the products.
• Catalysis can be regarded as a stabilization of the intermediate with respect to the state of the
• a catalyst is a substance that increases the rate of the reaction and is recovered substantially unchanged chemically at the end of the reaction.
• Enzymatic catalysis depends on the existence and discovery of naturally occurring enzymes with the appropriate specificity and catalytic function needed to perform a particular
• the present invention overcomes these limitations by providing a novel approach to catalysis.
• the invention provides a method for the preparation and use of monoclonal antibodies as convenient, readily obtainable, and inexpensive catalysts having a degree of specificity and efficiency of action not previously achievable in the catalytic arts.
• the present invention relates to a method involving monoclonal antibodies for increasing the rate of a chemical reaction involving conversion of at least on e reactant to at least one product.
• the reactant(s) is (are) contacted with an appropriate organic compound.
• the monoclonal antibody under conditions suitable for the formation of a complex between the monoclonal antibody ant the reactant(s).
• the complexed reactant(s) is (are) converted to the product(s), and the product(s) released from the complex.
• this invention is useful in increasing the rate of chemical reactions which can also be catalyzed by enzymes such as oxidoreductases,
• transferases hydrolases, lyases, isomerases, and
• this invention is useful in increasing the rate of chemical reactions for which no catalytic enzymes are known. Such reactions include, among others, oxidations, reductions, additions,
• the rate of the chemical reaction may be increased by more than a hundredfold and preferably more than ten thousandfold.
• a solution phase or emulsion reaction system including a protic solvent, preferably water, maintained at a pH value between about 6.0 and about 8.0, preferably between about 6.0 and about 7.5, and maintained at a temperature from about 4°C to about 50°C, preferably between about 20°C and about 45°C.
• a protic solvent preferably water
• the ionic strength ⁇ 1 ⁇ 2 ⁇ c-z 2 i , where c is the
• concentration and z is the charge of an ionic solute. It should be maintained at a value below 2.0 moles/liter, preferably between about 0.1 and 1.5 moles/liter.
• the method of this invention may be carried out under reduced or elevated pressure, but preferably is practiced at ambient pressure.
• the monoclonal antibody is further
• r 1 is the rate of formation of the complex between the antibody and the reactant and where r o is the rate of the chemical
• anti-idiotype monoclonal antibodies are prepared for known enzyme-substrate systems.
• the anti-idiotype monoclonal antibodies can be used to increase the rate of conversion of the substrate to the product and are not subject to allosteric control.
• the present invention provides methods for increasing the rate of a chemical reaction involving conversion of at least on reactant to at least one product.
• the reactant(s) is (are) contacted with at least one appropriate monoclonal antibody under suitable conditions permitting the formation of a complex between the reactant(s)
• the monoclonal antibodies useful in the present invention are prepared by modification of the technique disclosed by Koprowski et al. in U.S. Patent No.
• a series of monoclonal antibodies directed to the reactant are prepared under suitable conditions. This involves first immunizing BALB/C mice with an appropriate antigen.
• the antigen may be the desired reactant; the desired reactant bound to a peptide or other carrier molecule; a reaction
• Analog encompasses isomers, homologs, or other compounds sufficiently resembling the reactant in terms of chemical structure such that an antibody raised against the analog may participate in an immunological reaction with the reactant but will not necessarily catalyze a reaction of the analog.
• the reaction to be catalyzed is the cleavage of o-nitrophenyl-ß-D-galactoside
• the antigen may be the analog dinitrophenol bound to a carrier, e.g., keyhole limpet hemocyanin, or the antigen may be the reactant o- nitrophenyl-ß-D-galactoside.
• reaction to be catalyzed is the condensation of two molecules of aminolevulinic acid to yield porphobilinogen:
• the antigen may be the analog 3-glycyl-4-hydroxy-4- methol-1,5-hepatanedoic acid:
• Antibody-producing lymphocytes are then removed from the spleens of the immunized mice and hybridized with myeloma cells such as SP2/0 cells to produce hybridoma cells. These hybridoma cells are then plated in the wells of microtiter plates. The series of monoclonal antibodies being produced by the hybridoma cells is screened under appropriate conditions to identify monoclonal antibodies which catalyze the desired reaction under appropriate conditions. Screening may be conveniently accomplished by treating a standardized solution of the reactant with an aliquot of medium withdrawn from a microtiter well and measuring the presence of the desired product by
• This measurement may be readily conducted, for example, by spectrophotometric methods or by gas-liquid or high pressure liquid
• hybridoma cells producing catalytic monoclonal antibodies are identified. The selected hybridoma cells are then cultured to yield colonies.
• mice such as syngeneic BALB/C mice are inoculated intraperitoneally with the selected hybridoma cells and produce tumors, generally within two or three weeks. These tumors are accompanied by the production of ascites fluid which contains the desired monoclonal antibodies.
• monoclonal antibodies are then separately recovered from the ascites fluid by conventional methods such as
• K is defined as the ratio of the
• K is greater than 10 2 .
• Equations (2), (3), and (4) describe the kinetic characteristics of the monoclonal antibodies useful in this invention.
• Equation (2) states that 4 1 , defined as the rate of formation of the complex between the antibody and the reactant, must be greater than r o where r o is the rate of the chemical reaction in the absence of
• Equation (3) states that r 2 , defined as the rate of conversion of the complexed reactant to the complexed product, must be greater than r o .
• Equation (4) states that r 3 , defined as the rate of release of the product from the complex, must be greater than r o .
• the monoclonal antibodies of this invention can effect a rate acceleration in chemical reactions preferably by more than a factor of 10 2 and even more preferably by more than a factor of 10 4 .
• the separately recovered monoclonal antibodies are contacted with the reactant under suitable conditions permitting the formation of a complex between the monoclonal
• suitable conditions for complex formation encompass solution phase and emulsion reaction systems including a protic solvent, preferably water, maintained at a pH value between about 6.0 and about 8.0, preferably between about 6.0 and about 7.5, and at a temperature from about 4°C to about 50°C, preferably from about 20°C to about 45°C.
• a protic solvent preferably water
• the ionic strength, ⁇ 1 ⁇ 2 ⁇ c i z 2 i , where c is the concentration and z is the electronic charge of an ionic solute, should be maintained at a value below about 2.0 moles/liter, preferably between 0.1 and 1.5 moles/liter.
• the method of this invention may be carried out at reduced or elevated pressure, but preferably is practiced at ambient pressure.
• suitable conditions also include the use of support materials to which the monoclonal antibody is attached. Such support materials are well known to those of ordinary skill in the art as are methods for attaching monoclonal antibodies to them.
• the method of this invention is widely useful to increase the rate of any chemical reaction.
• This method is applicable, for example, to chemical reactions involving the conversion of one reactant to one product.
• Such reactions include the conversion of an ⁇ -amino acid, and can be illustrated by the conversion of indole pyruvic acid to L-tryptophan.
• Another example is
• polynucleotide being used herein to include both poly- and oligonucleotides.
• the method of this invention is also applicable to chemical reactions of more complex stoichiometry.
• reactants to one product can also be increased in accordance with this invention.
• An example of such a reaction is the conversion of two molecules of amino-levulinic acid into one molecule of
• the method is also useful for reactions
• Such reactions may be illustrated by the conversion of a ⁇ -D-galactoside into D-galactose and a second product, as well as by the cleavage of a
• polypeptide and “polysaccharide” include poly- and oligopeptides and poly- and
• the method has further utility in increasing the rate of chemical reactions involving the conversion of one reactant into multiple products.
• Such reactions include, among others, the conversion of polynucleotides, polypeptides, and polysaccharides into fragments derived respectively therefrom.
• a reactant is contacted with more than one monoclonal antibody, each of which is directed to a different determinant on the reactant.
• the reactant is a polynucleotide and the monoclonal antibodies are directed to different nucleotide sequences within the polynucleotide, specific polynucleotide fragments may be cleaved from the reactant.
• the method is also useful in increasing the rate of reactions involving the conversion of two
• Such reactions include the exchange of functional groups between one reactant and a second reactant to yield two new products, e.g.,
• monoclonal antibodies may be prepared which interact with a polynucleotide only at a specific
• nucleotide sequence or with a peptide only at a specific amino acid sequence.
• the method of this invention may be used to increase the rate of reactions which may also be used.
• the enzyme may be an oxidoreductase, such as alcohol dehydrogenase, glucose oxidase, xanthine oxidase, dihydrouracil dehydrogenase. or L-amino acid oxidase; a transferase such as
• guanidinoacetate methyl transferase serine hydroxymethyl transferase, or aspartate aminotransferase
• a hydrolase such as acetylcholesterase, glucose-6-phosphatase, or a phosphodiesterase
• a lyase such as pyruvate
• decarboxylase aldolase or histidine ammonia-lyase
• an isomerase such as ribulose phosphate epimerase, or a ligase such as tyrosyl-tRNA synthase or acetyl CoA carboxylase.
• this method may be used to increase the rate of conversion of two molecules of aminolevulinic acid to one molecule of
• porphobilinogen a reaction catalyzed in nature by the enzyme aminolevulinic acid dehydratase; to increase the rate of conversion of a cyclic polynucleotide to a linear polynucleotide or of a linear polynucleotide to two or more fragments thereof, reactions involving cleavage of a specific phosphodiester bond in the polynucleotide catalyzed in nature by phosphodiesterase (restriction) enzymes; to increase the rate of conversion of an ⁇ -keto acid such as indole pyruvic acid to an ⁇ -amino acid such as L-tryptophan, a reaction involving transfer of an amino group from a reactant to a product catalyzed in nature by a transaminase enzyme; and to increase the rate of conversions of a ⁇ -D-galactoside to D-galactose and a second product, a reaction involving cleavage of a
• monoclonal antibodies directed to an antigen which is a known substrate for an enzyme are prepared and used to increase the rate of conversion of the substrate to the product. This method is useful, for example, in
• the series of antibodies so produced is screened under suitable conditions to identify a first monoclonal antibody which binds to the active site of the enzyme.
• a monoclonal antibody may be identified by screening for antibodies which under appropriate
• This first monoclonal antibody so identified is separately recovered according to the general technique and is used to inoculate fresh BALB/C mice. By following the general technique, a series of monoclonal antibodies to the first monoclonal antibody is produced. The antibodies so produced are termed "anti-idiotype" monoclonal
• the series of anti-idiotype monoclonal antibodies is then screened according to the general method to identify anti-idiotype monoclonal antibodies which bind the antigen (substrate) under suitable
• suitable conditions are meant conditions within the parameters described above for antibody-reactant complex formation.
• An anti-idiotype monoclonal antibody so produced and separately recovered may be used in accordance with this invention to increase the rate of conversion of substrate to product.
• Allosteric enzymes are enzymes which are stimulated or inhibited by a modulator molecule which may be the substrate, the product, or some other molecule.
• a modulator molecule which may be the substrate, the product, or some other molecule.
• the kinetic behavior of allosteric enzymes is greatly altered by variations in the concentration of the modulator(s).
• a relatively simple example of allosteric behavior may be illustrated by an enzyme which is subject to feedback inhibition. In such a case, the catalytic efficiency of the enzyme decreases as the concentration of an immediate or subsequent product increases. Use of such enzymes in many applications is thus limited and requires continuous removal of product.
• use of the appropriate anti-idiotype monoclonal antibody which is not subject to allosteric control in place of the enzyme can thus overcome the problems and limitations of allosterism.
• cofactors such as
• pyridoxal phosphate nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate, flavin adenine dinucleotide, adenosine triphosphate, thiamine pyrosphosphate, flavin mononucleotide, biotin,
• a monoclonal antibody may be prepared in accordance with this invention that combines the relatively inefficient catalytic capabilities of a cofactor alone with the highly specific and efficient advantages of the monoclonal antibody. To prepare such a monoclonal antibody, mice are inoculated with the
• a series of hybridoma cells is then prepared according to the general method and screened for the production of monoclonal antibodies which can complex with free cofactor and reactant, increase the rate of the chemical reaction, and release the product.
• monoclonal antibody directed against indole pyruvic-acid-pyridoxamine phosphate imine for example, selectively increases the rate of conversion of indole pyruvic acid to the amino acid tryptophan.
• the appropriate cofactor is added to the reaction mixture preferably in an amount at least equimolar to that of the monoclonal antibody.
• Mouse mammary tumor virus RNA may be extracted by conventional methods from a commercially available mouse mammary tumor virus, e.g., MTV ATCC VR-731 (American Type Culture Collection).
• the analog 3-glycyl-4-hydroxy-4-methyl-1,5-heptanedioic acid may be prepared by conventional synthetic methods, e.g., by base catalyzed condensation suitably protected molecules of aminolevulinic acid and levulinic acid (Aldrich) followed by deprotection and HPLC purification.
• mice One group of female BALB/C mice (Group 1 in Table 1) at 7 weeks of age were inoculated intravenously with 10 mg of o-nitrophenyl- ⁇ -D-galactoside (ONPG) and intraperitoneally with 12 mg of ONPG on day 0.
• the ONPG was dissolved in 0.1M phosphate buffer at pH 7.3 at a concentration of 25 mg/ml and warmed to 37°C.
• the mice On day 33, the mice were inoculated intraperitoneally with 12.5 mg of ONPG in incomplete Freund's adjuvant.
• the ONPG phosphate buffer solution was mixed with an equal volume of incomplete Freund;'s adjuvant and emulsified prior to inoculation.
• a blood sample was obtained from each mouse on day 54. The serum was separated from the blood sample by centrifugation and stored at 4°C.
• mice inoculated as in Example 1 were inoculated intraperitoneally on day 91 with dinitrophenol (DNP) coupled to keyhole limpet hemocyanin (KLH) and emulsified in incomplete Freund's adjuvant.
• the inoculum contained 10 mg of protein as determined by the method of Bradford, 1976, Anal . Biochem . 72:248.
• the dinitrophenol was coupled to KLH by the method of Little and Eisen, 1967, Meth . Immunol . Immunochem . 1 : 12.
• the DNP-KLH inoculation was repeated on day 101.
• the inoculum was prepared as described for the inoculum used on day 91.
• a blood sample was obtained from each mouse on day 105 and the serum separated by centrifugation and stored at 4°C.
• mice (Group 2 in Table 1) were inoculated intraperitoneally with 50 mg or 100 mg of ONPG emulsified in complete Freund's adjuvant on day 0, intravenously, with 10 mg of ONPG in 0.1M phosphate buffer (pH 7.3) on day 30, and intraperitoneally with 12.5 mg of ONPG in incomplete Freund's adjuvant (25mg/ml) on day 63.
• the mice were bled 9 days later, serum was separated by centrifugation and stored at 4°C.
• Example 5 Mice inoculated as in Example 3 were then inoculated, intraperitoneally, with 10 mg of DNP-KLH emulsified in incomplete Freund's adjuvant on days 121 and 131, and bled on day 135. Serum was separated by centrifugation and stored at 4°C.
• Example 5
• the catalytic activity of antibodies which react with ONPG was determined in the following way.
• Examples 1 and 3 as described above was contacted for 18 hours at 23°C with 50 microliters of ONPG in PBS-Tween buffer containing 1% BSA.
• 50 mg of the enzyme ⁇ -D-galactosidase in 50 microliters of PBS-Tween-BSA buffer was contacted with the ONPG solution.
• the enzyme ⁇ -D-galactosidase had catalytic activity.
• Serum collected in Examples 2 and 4 from mice which had received additional inoculations with DNP coupled to KLH was then assayed.
• the serum was tested for the presence of antibodies that bind ONPG by the method described above. It was shown that serum from the immunized mice contained anti-ONPG antibodies. Serum at a dilution of 1:5,120 yielded a positive reaction for the presence of anti-ONPG antibodies. This demonstrated that additional immunizations with an analog coupled to KLH had resulted in an increased concentration of anti-ONPG antibodies in the serum. No reactions were seen using serum from mice that had not been immunized.
• Example 4 and assayed as in Example 5 are sacrificed and their spleens removed.
• the spleens of ten (10) mice are gently teased and passed through a fine nylon screen to yield a lymphocyte (spleen cell) suspension.
• Myeloma cells derived from the SP2/0 line are grown in HB101 medium supplemented with 2% fetal bovine serum, penicillin, and streptomycin (complete HB101).
• SP2/0 cells are subcultured daily for three days before use in cell fusions and are seeded at densities not exceeding 10 cells/ml.
• the SP2/0 cells are washed once in RPMI-1640 before fusion.
• a suspension of lymphocytes prepared as in Example 6 is mixed in a 4:1 ratio with a suspension of SP2/0 myeloma cells prepared according to Example 7.
• the cells are pelleted and a polyethylene glycol (PEG) 1450 (Eastman-Kodak, Rochester, New York) solution (containing 50% PEG 25/vol in RPMI-1640) is then added dropwise to the cell pellets at a ratio of 1 ml of PEG to 1.6x10 5 lymphocytes.
• PEG polyethylene glycol
• the cell suspension is centrifuged at 200xg for 5 min., the supernatant is removed and the cells are gently suspended in complete HB101 at a final
• This final cell suspension is then dispensed in 100 ⁇ l volumes in wells of a 96-well microtiter plate and cultured at 37°C.
• HAT medium Complete HB101 supplemented with 1 x 10 -4 M hypoxanthine, 4.0 x 10 -4 M aminoptenn, and 1.6 x 10 -5 M thymidme
• Cells are fed every 2 to 3 days by aspirating approximately 100 ⁇ l of medium from each well and adding
• Microtiter wells containing hybridoma cells prepared according to Example 8 which produce antibodies capable of catalyzing the cleavage of o-nitrophenyl- ⁇ -D-galactoside into o-nitrophenol and D-galactose are assayed as follows: a second 96-well microtiter plate
• the assay plate (the assay plate) is prepared containing a 0.05 M
• Example 11 A portion of each catalytic hybridoma cell suspension identified in Example-9 is seeded in each well of a new microtiter plate.
• the plating efficiency of the hybrid cells is 50% (i.e., 50% of the seeded cells multiply to form colonies). With this procedure, 80-100% of the wells yield colonies of hybrid cells within two (2) weeks.
• the hybridoma cells are again tested for catalytic antibody production by the method described in Example 9.
• Hybridoma cells which continue to produce catalytic antibodies are again clone using thymocyte feeder cells, but at densities of one hybrid cell per three wells. The procedure is repeated whenever less than 90% of the clones from a specific set are making antibodies.
• Example 11 A portion of each catalytic hybridoma cell suspension identified in Example-9 is seeded in each well of a new microtiter plate. The plating efficiency of the hybrid cells is 50% (i.e., 50% of the seeded cells multiply to form colonies). With this procedure, 80-100% of the wells
• Intraperitoneal inoculation of 10 hybrid cells selected according to Example 9 into snygeneic BALB/C mice induces palpable tumors in more than 90% of the inoculated mice within 2 to 3 weeks. These tumors are accompanied by the production of ascites fluids (0.5 to 3.0 ml per mouse).
• the immunoglobulin concentration in ascites fluids and sera of hybridoma-bearing mice is determined by a radial immunodiffusion assay. The concentrations of monoclonal antibodies in the serum and ascites fluid of an individual mouse are roughly
• the D-galactose is recovered by extracting the filtrate with three 100 ml portions of diethyl ether.
• the ether portions are combined, washed once with 1.0 N sodium bicarbonate, dried over magnesium sulfate, filtered and concentrated under reduced pressure to yield D-galactose.
• the aqueous portion is then combined with the sodium bicarbonate wash and acidified to pH 3 by the addition of 5 N hydrochloric acid.
• the acidified aqueous portion is then extracted three times with ether.
• the etheral extracts are combined, dried over magnesium sulfate, filtered and concentrated at reduced pressure to yield 9-nitrophenol.
• the o-nitrophenol and D-galactose may be further purified by HPLC or by recrystallization.
• Spleen cells for hybridization are prepared according to the method of Example 6, except that the
• mice are immunized with 3-glycyl-4-hydroxy-4-methyl-1,5-heptanedioic acid.
• Myeloma cells are prepared according to Example 7.
• the spleen cells and the myeloma cells are then fused to yield hybridoma cells according to the method of Example 8.
• the hybridoma cells are then screened by a modification of the method of Example 9 in which the assay substrate is aminolevulinic acid (0.05M) and the assay tests for the appearance of an HPLC-peak corresponding to PBG.
• the hybridoma cells so identified are cultured according to the method of Example 10 and are obtained from mice according to the method of
• reaction mixture is gently agitated for 2.0 hours.
• the monoclonal antibodies are then recovered from the
• reaction mixture by ultrafiltration.
• the reaction mixture is lyophilized, and the residue is
• a Schiff base is prepared by mixing 2.03 g (10 mmol) indole-3-pyruvic acid, 2.65 g (10 mmol)
• Spleen cells are prepared by the method of Example 6 except that the BALB/C mice are immunized with the Schiff base.
• the spleen cells so obtained are fused according to the method of Example 8 with myeloma cells prepared according to Example 7.
• the hybridoma cells are then screened by a modification of the method of
• Example 9 in which the substrate is a mixture of indole- 3-pyruvic acid (0.05M) and pyridoxamine-5-phosphate
• hybridoma cells so identified are cultured according to the method of
• Example 10 are obtained from mice by the method of
• reaction mixture is gently agitated for 2 hours.
• the monoclonal antibodies are then recovered by
• BSA bovine serum albumin
• RNA-protein (BSA) conjugate is then lyophilized and weighed into vials for storage under nitrogen at -77°C.
• BSA keyhole limpet hemocyanin
• OA ovalbumi ⁇
• RA rabbit serum albumin
• Spleen cells for hybridization are prepared according to the method of Example 6, except that the BALB/C mice are immunized with the BSA-bound 35S RNA prepared in A above.
• Myeloma cells are prepared
• Example 7 The spleen cells and the myeloma cells are then fused to yield hybridoma cells according to the method of Example 8.
• hybridoma cells so obtained are screened by incubating aliquots of the microtiter well contents with 35S RNA in 0.5M phosphate buffer (pH 6.1) containing 0.9% NaCl at 37°C for varying lengths of time. The RNA is then purified by phenol extraction. The number of fragments generated by antibody cleavage is determined by 2-dimensional polyacrylamide gel electrophoresis and the nucleotide sequence at each cleavage site is resolved. Both determinations are made according to the methods described by Schwartz et al., 1983, Cell 32: 853-869. By comparing the fragments obtained from RNA cleavage induced by the contents of each microtiter well with the Eco R1-induced fragments, hybridoma cells are selected which produce monoclonal antibodies capable of catalyzing
• hybridoma cells so identified are cultured according to the method of Example 10 and are obtained from mice by the method of Example 11.
• Mouse mammary tumor virus 35S RNA (50 mg) is added to 100 ml of distilled water buffered at pH 6.1 with 0.5M phosphate buffer containing 0.9% NaCl and maintained at 37°C.
• Monoclonal antibodies (5 mg)
• RNA is then purified by phenol extraction and the fragments purified by
• Anti-idiotype monoclonal antibodies to ⁇ -D-galactosidase A Preparation of monoclonal antibodies
• Spleen cells for hybridization are prepared according to the method of Example 6, except that the
• mice are immunized with the enzyme ⁇ -D-galactosidase.
• Myeloma cells are prepared according to Example 7.
• the spleen cells and the myeloma cells are then fused to yield hybridoma cells according to the method of Example 8.
• the hybridoma cells thus obtained are screened for production of monoclonal antibodies which bind to the active site of the enzyme. Screening is conveniently conducted by RIA assay of the competitive inhibition of the microtiter well contents against ⁇ -D- galactosidase and radio-labeled o-nitrophenyl- ⁇ -D-galactoside.
• Hybridoma cells so selected are then cultured according to the method of Example 10 and obtained in larger quantity from mice according to the method of Example 11.
• Spleen cells for hybridization are prepared according to the method of Example 6, except that the BALB/C mice are immunized with the monoclonal antibodies prepared and selected according to Example 7.
• the spleen cells and the myeloma cells are fused to yield hybridoma cells according to the method of Example 8.
• hybridoma cells thus obtained are first screened
• Hybridoma cells selected on the basis of the preliminary screening are then screened for allosterism. This is accomplished by measuring the presence of one of products according to Example 9, but at periodic time intervals. From the data so obtained, a reaction rate may be calculated. By repeating the assay in the presence of varying amounts of the reactant and again with varying amounts of the product not being measured, changes in the kinetic behavior of the antibody can be detected. In this manner, anti-idiotype monoclonal antibodies exhibiting allosteric control may be eliminated.
• the hybridoma cells producing non-allosteric anti-idiotype monoclonal antibodies are cultured according to the method of
• Example 10 obtained by propagation in mice according to the method of Example 11.
• the anti-idiotype monoclonal antibodies obtained in B may be used according to the method of Example 12.
• Example 20 The anti-idiotype monoclonal antibodies obtained in B may be used according to the method of Example 12.
• a catalytic antibody to hapten VI is isolated, which resembles the transition state for the hydrolysis of the underived R-enantiomer. It is used to selectively hydrolyze the R-enanti ⁇ mer of III to the phenol IV. The remaining ester of the desirable S-enantiomers is stable and so separation of the two enantiomers requires
• the substrate X can be used for screening for catalytic antibodies.
• Substrate X ( Figure 3) is added to each antibody-producing cell-line sample and the presence of catalytic activity will be measured by fluorescence of the 7-hydroxy-4-methylcoumarin that is generated. Strong fluorescence over time will indicate that a hybridoma cell line producing catalytic antibodies has been identified. As a result of using X for
• the R group in VI will become XI m order that the immunogen and the screening molecules resemble each other.
• the carboxyl group in XI is used to link structure VI to a carrier protein and is used for
• This immunogen will elicit antibodies that catalyze stereoselective cleavage of the chiral nitrophenyl ester substrate (2) :
• Monoclonal antibodies were obtained by standard protocols using lymphocytes from mice immunized with 4 linked to a protein carrier. Antibodies were screened for hydrolytic activity (25mm phosphate, pH 7.0, 25°C) by monitoring substrate depletion with high performance liquid 'chromatography. The rates of phenol release from the ester 1 in the presence of catalytic antibody 1 were determined spectrophotometrically. The initial rates as a function of substrate concentration followed Michaelis-Newton kinetics. Over this concentration range, there was no apparent substrate inhibition. The k cat /k uncat observed with catalytic antibody 1 were up to 167-fold rate acceleration.
• the catalytic activity was a property of the monoclonal antibody because: (1) neither the hydrolytically more labile coumarin ester corresponding to 1 nor the phenyl-t-hydroxypentanoate, which labels the important acetamidomethyl recognition element were substrates; (2) a second monoclonal antibody that bound 4 did not catalyze the liberation of phenol from 1; and (3) the reaction of monoclonal antibody 1 was competitively inhibited linearly by the additions of the transition state analog, the N-acetyl derivative of 2.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Genetics & Genomics (AREA)
• Biochemistry (AREA)
• General Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Microbiology (AREA)
• Biotechnology (AREA)
• General Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Medicinal Chemistry (AREA)
• Biophysics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biomedical Technology (AREA)
• Mycology (AREA)
• Analytical Chemistry (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Physical Or Chemical Processes And Apparatus (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=22893183

Family Applications (1)

Country Status (6)

Families Citing this family (2)

Citations (2)

Family Cites Families (2)

• 1989
  • 1989-08-22 ZA ZA896408A patent/ZA896408B/xx unknown
  • 1989-08-23 IL IL91397A patent/IL91397A0/xx unknown
  • 1989-08-25 AU AU42132/89A patent/AU4213289A/en not_active Abandoned
  • 1989-08-25 EP EP19890910248 patent/EP0431060A4/en not_active Ceased
  • 1989-08-25 JP JP1509369A patent/JPH04501656A/ja active Pending
  • 1989-08-25 WO PCT/US1989/003696 patent/WO1990002192A1/en not_active Application Discontinuation
• 1993
  • 1993-07-14 AU AU41956/93A patent/AU657864B2/en not_active Ceased

Patent Citations (2)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events